Clinical and economic evaluation of the use of biologic disease-modifying antirheumatic drugs and targeted synthetic antirheumatic drugs for ankylosing spondylitis in context of the Russian healthcare system
Objective: clinical and economic evaluation of the use of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs), Janus kinase inhibitors (iJAK), for the treatment of ankylosing spondylitis (AS).Patients and methods. Among comparison technologies for furthe...
Main Authors: | O. I. Ivakhnenko, T. V. Dubinina, T. V. Korotaeva, A. M. Lila |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2022-08-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1322 |
Similar Items
-
Pharmacoeconomic aspects of the targeted drugs use in psoriatic arthritis in context of the Russian healthcare system
by: O. I. Ivakhnenko, et al.
Published: (2022-10-01) -
Features of coxitis treatment in patients with ankylosing spondylitis
by: E. M. Agafonova, et al.
Published: (2018-06-01) -
Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis
by: R. O. Dreval
Published: (2021-02-01) -
Symptomatic therapy for ankylosing spondylitis
by: Vladimir Vasilyevich Badokin
Published: (2012-03-01) -
Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis
by: Rimma Mikhailovna Balabanova, et al.
Published: (2014-12-01)